Bivalirudin

Generic Name: Bivalirudin

Brand Names: Angiomax

Drug Type: Small Molecule

Chemical Formula: C_₉₈H_₁₃₈N_₂₄O_₃₃

CAS Number: 128270-60-0

Unique Ingredient Identifier: TN9BEX005G

Background: Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is administered intravenously. Because it can cause blood stagnation, it is important to monitor changes in hematocrit, activated partial thromboplastin time, international normalized ratio and blood pressure.

Indication: For treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.

Associated Conditions: Thrombosis

Clinical Trials

Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)

Not Applicable

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: prolonged continuous use of bivalirudin
Drug: bivalirudin use during ePCI

First Posted Date: 2019-10-09

Last Posted Date: 2022-08-09

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 330

Registration Number: NCT04120961

Locations: 🇨🇳
Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China

Bivalirudin in Elderly Patients Undergoing Elective Percutaneous Coronary Intervention.

Phase 4

Conditions: Acute Coronary Syndrome
Percutaneous Coronary Intervention
Anticoagulants and Bleeding Disorders
Aging

Interventions: Drug: Heparin
Drug: Bivalirudin

First Posted Date: 2019-08-06

Last Posted Date: 2019-08-06

Lead Sponsor: The First Affiliated Hospital of Dalian Medical University

Target Recruit Count: 240

Registration Number: NCT04046029

Locations: 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, China

Safety and Efficacy of Bivalirudin Versus Heparin for Systemic Anticoagulation in Extracorporeal Membrane Oxygenation

Phase 4

Conditions: Extracorporeal Membrane Oxygenation Complication
Anticoagulants

Interventions: Drug: Bivalirudin
Drug: Unfractionated heparin

First Posted Date: 2019-05-28

Last Posted Date: 2019-05-28

Lead Sponsor: Legacy Health System

Target Recruit Count: 34

Registration Number: NCT03965208

Locations: 🇺🇸
Legacy Health System, Portland, Oregon, United States

Bivalirudin in Elderly Patients With Acute ST-segment Elevation Myocardial Infarction

Phase 4

Conditions: Aged
STEMI
Percutaneous Coronary Intervention

Interventions: Drug: Heparin
Drug: Bivalirudin

First Posted Date: 2019-03-20

Last Posted Date: 2019-03-20

Lead Sponsor: The First Affiliated Hospital of Dalian Medical University

Target Recruit Count: 240

Registration Number: NCT03882775

Locations: 🇨🇳
The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

Bivalirudin With Prolonged Full Dose Infusion Versus Heparin Alone During Emergency PCI

Not Applicable

Conditions: ST Elevation Myocardial Infarction

Interventions: Drug: unfractionated Heparin
Drug: Bivalirudin

First Posted Date: 2019-01-30

Last Posted Date: 2022-06-13

Lead Sponsor: Shenyang Northern Hospital

Target Recruit Count: 6016

Registration Number: NCT03822975

Locations: 🇨🇳
Linquan County Peoples Hospital, Fuyang, Anhui, China
🇨🇳
Bengbu Second People's Hospital, Bengbu, Anhui, China
🇨🇳
Fu Yang People'S Hospital, Fuyang, Anhui, China

and more 82 locations